Scoop: Ex­e­Vir hits pause on lla­ma-de­rived Covid an­ti­body amid Omi­cron vari­ants, shifts fo­cus to sec­ond-gen work

Ex­e­Vir has re­turned to the draw­ing board af­ter paus­ing work on its first-gen­er­a­tion lla­ma-de­rived Covid-19 an­ti­body and is turn­ing its R&D fo­cus to­ward a pre­clin­i­cal sec­ond-gen at­tempt, End­points News has learned.

The Bel­gian biotech ter­mi­nat­ed a study of the an­ti­body, dubbed XVR011, last month due to “change in com­pa­ny strat­e­gy for phase 2 de­sign,” ac­cord­ing to an up­date on clin­i­cal­tri­als.gov. The biotech still awaits some da­ta to con­firm the scope of Omi­cron and its sub­vari­ants’ ef­fect on the an­ti­body, but Ex­e­Vir is like­ly to move for­ward with­out its first shot at treat­ing the pan­dem­ic dis­ease, CEO Torsten Mum­men­brauer told End­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER